Compare
Soliqua 100/33 vs. Tresiba

Soliqua 100/33 is a combination medication for diabetes that contains insulin glargine (a long-acting insulin) and lixisenatide (a glucagon-like peptide-1 (GLP-1) receptor agonist). It helps manage blood sugar levels along with diet and exercise in adults with Type 2 diabetes. The medication comes as a prefilled pen and is injected under the skin once a day within 1 hour before you eat your first meal of the day. Soliqua 100/33 commonly causes stomach-related side effects like nausea and diarrhea.

• Type 2 diabetes in adults

• Nausea (10%)
• Low blood sugar (8%)
• Common cold-like symptoms (7%)
• Diarrhea (7%)
• Headache (5%)

• Severe allergic reactions
• Inflammation of the pancreas (pancreatitis)
• Risk of high and low blood sugar levels
• Dangerously low blood sugar levels (hypoglycemia)
• Kidney damage
• Low blood potassium levels
• Fluid buildup and heart failure with certain diabetes medications
• Gallbladder problems
• Aspiration during anesthesia or sedation

Insulin degludec (Tresiba) is an ultra-long-acting insulin. It's used to manage blood sugar levels in adults and children with Type 1 diabetes or Type 2 diabetes. It's injected under the skin once per day. Insulin degludec (Tresiba) comes as a vial and FlexTouch pen. Side effects include common cold symptoms and headache. Tresiba is available as a brand-name medication and an unbranded biologic.

• Type 1 diabetes
• Type 2 diabetes

• Low blood sugar levels (up to 99%)
• Common cold (up to 24%)
• Upper respiratory tract infection (up to 12%)
• Headache (up to 12%)
• Diarrhea (up to 6%)
• Sinus infection (up to 5%)
• Stomach viral infection (up to 5%)

• Risk of infections with pen sharing
• Risk of high and low blood sugar levels
• Dangerously low blood sugar levels (hypoglycemia)
• Low blood potassium levels
• Swelling and heart failure when used with certain diabetes medications
• Allergic reactions